Cannabis and Opioid Use Disorder

Purpose

This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.

Condition

  • Opioid Use Disorder

Eligibility

Eligible Ages
Between 18 Years and 55 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Current opioid use disorder

Exclusion Criteria

  • Current medical conditions that require medical management

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Primary Purpose
Basic Science
Masking
Triple (Participant, Care Provider, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Intranasal Opioid Agonist
Participants will receive non-therapeutic, experimental doses of an opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intransally (snorting).
  • Drug: Inhaled vaporized cannabis
    Double-blind cannabis and placebo doses, administered through vaporizer
  • Drug: Intransal opioid
    Double-blind opioid and placebo doses, administered intranasal route
Experimental
Vaporized cannabis
Participants will receive non-therapeutic, experimental doses of active or placebo vaporized cannabis. Active cannabis/placebo will be administered once per session and will be administered via a vaporizer.
  • Drug: Inhaled vaporized cannabis
    Double-blind cannabis and placebo doses, administered through vaporizer
  • Drug: Intransal opioid
    Double-blind opioid and placebo doses, administered intranasal route

Recruiting Locations

UK Center for Clinical and Translational Science and nearby locations

Center on Drug and Alcohol Research
Lexington, Kentucky 40508
Contact:
Paul Nuzzo, MA
859-323-0002
pnuzz2@email.uky.edu

More Details

NCT ID
NCT05729932
Status
Recruiting
Sponsor
University of Kentucky

Study Contact

Paul Nuzzo, MA
859-323-0002
pnuzz2@email.uky.edu